02 April 2011
FDA Fast Track designations granted for both: the protease
cheap cialis BI 201335 plus standard-of-care and the interferon-free combination of BI 201335 with polymerase inhibitor, BI 207127
Not for U.S. media
INGELHEIM, Germany, 2 April 2011 - Boehringer Ingelheim today announced the study outline for the pivotal Phase III clinical
(
Read more... )